Search research articles
Contact Us
Filters
Showing results (231-240 of 289) with videos related to
Page
of 29
Sort By:
The Oncologist
|
March 14, 2020
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon
Shaheen Khan, Mitchell S von Itzstein, Rong Lu, et al.
Pediatric Blood & Cancer
|
September 12, 2025
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors
Matthew E Campbell, Sonja Stutzman, Sharon Primeaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Therapeutic Advances in Medical Oncology
|
November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
Frontiers in Immunology
|
May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
Mitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
JCO Oncology Practice
|
May 10, 2021
Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?
Mitchell S von Itzstein, Mary L Smith, Elda Railey, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Murtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, et al.
Page
of 29
Search research articles
Search
Showing results (231-240 of 289) with videos related to
Sort By:
Page
of 29
The Oncologist
|
March 14, 2020
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon
Shaheen Khan, Mitchell S von Itzstein, Rong Lu, et al.
Pediatric Blood & Cancer
|
September 12, 2025
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors
Matthew E Campbell, Sonja Stutzman, Sharon Primeaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Therapeutic Advances in Medical Oncology
|
November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
Frontiers in Immunology
|
May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
Mitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
JCO Oncology Practice
|
May 10, 2021
Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?
Mitchell S von Itzstein, Mary L Smith, Elda Railey, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Murtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, et al.
Page
of 29